Vertex Pharma (VRTX) Misses Q4 EPS by 4c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
February 10, 2025 4:01 PM ESTFull year product revenue of $11.02 billion, a 12% increase compared to full year 2023
Company provides full year 2025 total revenue guidance of $11.75 to $12.0 billion
ALYFTREK approved in the U.S. for patients ages 6+ with cystic fibrosis; JOURNAVX approved in the U.S. for moderate-to-severe acute pain
Diverse late-stage clinical pipeline accelerates with four programs in pivotal development
Stuart Arbuckle, Chief Operating Officer, announces intent to retire July 1, 2025; as part of planned transition, Charlie Wagner, Chief Financial Officer, to assume additional role of Chief Operating... More
